Phase 1 First-in-human Study of JS014

Inclusion Criteria:

* Older 18 years of age or per local regulation
* Subjects with advanced cancer or lymphoma who have no standard therapy available, ineligible for standard therapy or unwilling to receive cytotoxic therapy .
* ECOG PS 0-1
* A life expectancy longer than three months
* Adequate organ functions
* Able to adopt effective contraceptive measures

Exclusion Criteria:

* Known history of allergies to JS014 or IL-21 or human serum albumin or pembrolizumab (Ib only)
* Subjects who have received major surgery less than 4 weeks before 1st infusion of JS014
* Subjects who has a history of immune-related adverse events in prior immunotherapy.
* Subjects who have received immunosuppressive therapy less than 4 weeks before 1st infusion of JS014.
* Subjects who have two or more primary cancers in the past 5 years.
* Newly diagnosed or symptomatic brain metastases.
* Subjects who have received prior anti-cancer therapy with residual toxicities greater than grade 2.
* Subjects who have a history of autoimmune disease in 2 years.
* Subjects who have active infection, or uncontrollable hypertension, unstable angina, active peptic ulcer, recent acute myocardial infarction, severe congestive heart failure, or unhealed wound.
* Subjects with active hepatitis B or hepatitis C.
* Subjects who are pregnant or breast feeding.
* Subjects who primary immune deficiency.